Abstract:Objective:The epidermal growth factor receptor(EGFR) has emerged as an attractive therapeutic target. The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib have already been on market in China for the treatment of advanced non-small cell lung cancer (NSCLCs).EGFR mutation is an important predictor of response to TKI.Most data about Chinese EGFR mutation are from south region.This presentation is to analyze the incidence and profile of mutations of EGFR in North Chinese patients with NSCLC. Methods: Fresh frozen specimens of fifty north Chinese cases of NSCLC were collected,and mutations of exons 18, 19 ,20 and 21 of the EGFR were detected by PCR and gene sequencing. Results: Overall, we detected 15 EGFR mutations (30%) ,including 6 cases of in-frame deletion del E746-A750 in exon19 and 9 cases of substitution in exon 21(all were L858R except one L861Q).Mutation rate was significantly higher in femal(12/23,52 %)than in male(3/27,11%),P=0.002 ,and significantly higher in andenocarcinoma and bronchioloalveolar cancer (13/26,50 %)than in squamous cell carcinoma (2/20 ,10%),P=0.005.Mutation rate in non-smokers was not significantly higher than that in smokers (10/25,40%vs 5/25,20% ,P=0.217).Compared with the data from other regions,we can see that there was no significant difference in the mutation profile among the patients from north and south China except Yunnan. Conclusion: The mutation profile of EGFR in north China was almost similar with that in south China. There were only two main kinds of mutation in the north,and we can detect them specially and simplely.

Analysis of EGFR Mutation in Chinese Non-Small Cell Lung Cancer Patients